{
  "as_of_date": "October 14, 2025",
  "programs": [
    {
      "asset": "AKEEGA (niraparib/abiraterone)",
      "indication": "M1 Metastatic Castration-Sensitive Prostate Cancer",
      "phase": null,
      "trial_or_program": "AMPLITUDE",
      "partner": "TESARO, an oncology-focused business within GSK",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06392841",
          "title": "Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
            "Deleterious HRR Gene Mutation",
            "BRCA1 Gene Mutation",
            "BRCA2 Gene Mutation",
            "BRIP1 Gene Mutation",
            "CHEK2 Gene Mutation",
            "FANCA Gene Mutation",
            "PALB2 Gene Mutation",
            "RAD51B Gene Mutation",
            "RAD54L Gene Mutation"
          ],
          "lead_sponsor": "Qian Qin",
          "collaborators": [
            "UT Southwestern Comprehensive Cancer Center",
            "Janssen, LP"
          ],
          "interventions": [
            "Androgen Deprivation Therapy (ADT)",
            "Niraparib/Abiraterone Acetate DAT",
            "Abiraterone Acetate",
            "Prednisone",
            "Docetaxel"
          ],
          "last_update": "2025-10-20",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06392841"
        },
        {
          "nct_id": "NCT06329830",
          "title": "Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study",
          "overall_status": "WITHDRAWN",
          "phase": "Phase 2",
          "conditions": [
            "Metastatic Prostate Cancer",
            "Castration-resistant Prostate Cancer",
            "Metastatic Castration-resistant Prostate Cancer"
          ],
          "lead_sponsor": "Baptist Health South Florida",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "177Lu-PSMA-617",
            "Niraparib abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2024-09-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06329830"
        },
        {
          "nct_id": "NCT03903835",
          "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Karolinska Institutet",
          "collaborators": [
            "The Swedish Research Council",
            "Kom Op Tegen Kanker",
            "Janssen Pharmaceutica N.V., Belgium",
            "AstraZeneca",
            "Cancerfonden"
          ],
          "interventions": [
            "Enzalutamide Oral Capsule",
            "Abiraterone Oral Tablet",
            "Carboplatin",
            "Cabazitaxel 60 mg Solution for Injection",
            "Docetaxel Injectable Solution",
            "Radium Chloride Ra-223",
            "Niraparib plus Abiraterone acetate plus Prednisone",
            "Capivasertib plus Docetaxel",
            "Apalutamide",
            "Darolutamide"
          ],
          "last_update": "2025-04-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Smoldering Multiple Myeloma",
      "phase": null,
      "trial_or_program": "AQUILA",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03289299",
          "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "International Myeloma Foundation",
          "collaborators": [
            "Amgen",
            "Janssen Scientific Affairs, LLC",
            "Celgene",
            "Trevie, Inc."
          ],
          "interventions": [
            "Carfilzomib",
            "Lenalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2023-12-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03289299"
        },
        {
          "nct_id": "NCT04396496",
          "title": "A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "POEMS Syndrome"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2023-11-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04396496"
        },
        {
          "nct_id": "NCT03384654",
          "title": "An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Vincristine",
            "Prednisone",
            "Doxorubicin",
            "Peg-asparaginase",
            "Cyclophosphamide",
            "Cytarabine",
            "6-mercaptopurine",
            "Methotrexate"
          ],
          "last_update": "2025-05-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03384654"
        },
        {
          "nct_id": "NCT07075510",
          "title": "A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Plasma Cell Disorder"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07075510"
        },
        {
          "nct_id": "NCT04140162",
          "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Michigan Rogel Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone"
          ],
          "last_update": "2024-10-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04140162"
        },
        {
          "nct_id": "NCT05849610",
          "title": "An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High-Risk de Novo Multiple Myeloma"
          ],
          "lead_sponsor": "PETHEMA Foundation",
          "collaborators": [
            "Janssen Pharmaceutica N.V., Belgium"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-03-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05849610"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT03187262",
          "title": "A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Waldenström Macroglobulinemia"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [
            "Daratumumab"
          ],
          "last_update": "2022-11-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03187262"
        },
        {
          "nct_id": "NCT03500445",
          "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Myeloma",
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Chicago",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "Amgen"
          ],
          "interventions": [
            "Daratumumab",
            "Carfilzomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03500445"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "DARZALEX (daratumumab)",
      "indication": "Frontline multiple myeloma transplant ineligible",
      "phase": null,
      "trial_or_program": "CEPHEUS",
      "partner": "Genmab A/S",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT03289299",
          "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Smoldering Multiple Myeloma"
          ],
          "lead_sponsor": "International Myeloma Foundation",
          "collaborators": [
            "Amgen",
            "Janssen Scientific Affairs, LLC",
            "Celgene",
            "Trevie, Inc."
          ],
          "interventions": [
            "Carfilzomib",
            "Lenalidomide",
            "Daratumumab",
            "Dexamethasone"
          ],
          "last_update": "2023-12-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03289299"
        },
        {
          "nct_id": "NCT04396496",
          "title": "A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "POEMS Syndrome"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2023-11-13",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04396496"
        },
        {
          "nct_id": "NCT03384654",
          "title": "An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Daratumumab",
            "Vincristine",
            "Prednisone",
            "Doxorubicin",
            "Peg-asparaginase",
            "Cyclophosphamide",
            "Cytarabine",
            "6-mercaptopurine",
            "Methotrexate"
          ],
          "last_update": "2025-05-25",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03384654"
        },
        {
          "nct_id": "NCT07075510",
          "title": "A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Plasma Cell Disorder"
          ],
          "lead_sponsor": "University of Maryland, Baltimore",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Daratumumab Injection"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07075510"
        },
        {
          "nct_id": "NCT04140162",
          "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Michigan Rogel Cancer Center",
          "collaborators": [
            "Janssen Scientific Affairs, LLC"
          ],
          "interventions": [
            "Daratumumab",
            "Lenalidomide",
            "Bortezomib",
            "Dexamethasone"
          ],
          "last_update": "2024-10-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04140162"
        },
        {
          "nct_id": "NCT05849610",
          "title": "An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "High-Risk de Novo Multiple Myeloma"
          ],
          "lead_sponsor": "PETHEMA Foundation",
          "collaborators": [
            "Janssen Pharmaceutica N.V., Belgium"
          ],
          "interventions": [
            "Daratumumab",
            "Bortezomib",
            "Lenalidomide",
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-03-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05849610"
        },
        {
          "nct_id": "NCT07149857",
          "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel",
            "Cyclophosphamide",
            "Induction therapy",
            "Fludarabine"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
        },
        {
          "nct_id": "NCT03187262",
          "title": "A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Waldenström Macroglobulinemia"
          ],
          "lead_sponsor": "Dana-Farber Cancer Institute",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [
            "Daratumumab"
          ],
          "last_update": "2022-11-23",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03187262"
        },
        {
          "nct_id": "NCT03500445",
          "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Myeloma",
            "Multiple Myeloma"
          ],
          "lead_sponsor": "University of Chicago",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "Amgen"
          ],
          "interventions": [
            "Daratumumab",
            "Carfilzomib",
            "Lenalidomide",
            "Dexamethasone"
          ],
          "last_update": "2025-10-03",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03500445"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)",
      "phase": null,
      "trial_or_program": "GLOW",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT02315326",
          "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
            "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Pharmacyclics LLC.",
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Ibrutinib",
            "HD- Methotrexate (MTX)",
            "Rituximab + HD- Methotrexate (MTX)",
            "procarbazine"
          ],
          "last_update": "2025-07-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
        },
        {
          "nct_id": "NCT01236391",
          "title": "Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Mantle Cell Lymphoma"
          ],
          "lead_sponsor": "Pharmacyclics LLC.",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "PCI-32765"
          ],
          "last_update": "2015-08-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01236391"
        },
        {
          "nct_id": "NCT04010968",
          "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Intermediate Risk Chronic Lymphocytic Leukemia",
            "Fit Patients",
            "Risk-Adapted and MRD-Driven Strategy"
          ],
          "lead_sponsor": "French Innovative Leukemia Organisation",
          "collaborators": [
            "AbbVie",
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "venetoclax and ibrutinib (I+VEN)",
            "FCR"
          ],
          "last_update": "2025-11-26",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
        },
        {
          "nct_id": "NCT01820936",
          "title": "Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Healthy Volunteers"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [
            "Pharmacyclics LLC."
          ],
          "interventions": [
            "Sequence 1: PCI-32765",
            "Sequence 2: PCI-32765",
            "Sequence 3: PCI-32765",
            "Sequence 4: PCI-32765",
            "Sequence 5: PCI-32765"
          ],
          "last_update": "2014-07-15",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01820936"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "IMBRUVICA (ibrutinib)",
      "indication": "Frontline Mantle Cell Lymphoma",
      "phase": null,
      "trial_or_program": "Triangle",
      "partner": "Pharmacyclics, LLC, an AbbVie company",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT02315326",
          "title": "A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
            "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
          ],
          "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
          "collaborators": [
            "Pharmacyclics LLC.",
            "Janssen Biotech, Inc."
          ],
          "interventions": [
            "Ibrutinib",
            "HD- Methotrexate (MTX)",
            "Rituximab + HD- Methotrexate (MTX)",
            "procarbazine"
          ],
          "last_update": "2025-07-01",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02315326"
        },
        {
          "nct_id": "NCT01236391",
          "title": "Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Mantle Cell Lymphoma"
          ],
          "lead_sponsor": "Pharmacyclics LLC.",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "PCI-32765"
          ],
          "last_update": "2015-08-28",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01236391"
        },
        {
          "nct_id": "NCT04010968",
          "title": "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia: a Randomized Phase II Trial Comparing FCR and a Chemo-free Combination of Venetoclax and Ibrutinib. A FILO Study",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Intermediate Risk Chronic Lymphocytic Leukemia",
            "Fit Patients",
            "Risk-Adapted and MRD-Driven Strategy"
          ],
          "lead_sponsor": "French Innovative Leukemia Organisation",
          "collaborators": [
            "AbbVie",
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "venetoclax and ibrutinib (I+VEN)",
            "FCR"
          ],
          "last_update": "2025-11-26",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04010968"
        },
        {
          "nct_id": "NCT01820936",
          "title": "Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765",
          "overall_status": "COMPLETED",
          "phase": "Phase 1",
          "conditions": [
            "Healthy Volunteers"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [
            "Pharmacyclics LLC."
          ],
          "interventions": [
            "Sequence 1: PCI-32765",
            "Sequence 2: PCI-32765",
            "Sequence 3: PCI-32765",
            "Sequence 4: PCI-32765",
            "Sequence 5: PCI-32765"
          ],
          "last_update": "2014-07-15",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT01820936"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer",
      "phase": null,
      "trial_or_program": "SunRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Frontline Non Small Cell Lung Cancer in combination with chemotherapy",
      "phase": null,
      "trial_or_program": "PAPILLON",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": null,
      "phase": null,
      "trial_or_program": "PALOMA-3",
      "partner": null,
      "notes": "Subcutaneous",
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "Bleximenib",
      "indication": "Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine",
      "phase": null,
      "trial_or_program": "cAMeLot-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma TNI",
      "phase": null,
      "trial_or_program": "CARTITUDE-5",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        }
      ],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
      "indication": "Frontline Multiple Myeloma Transplant Eligible vs ASCT",
      "phase": null,
      "trial_or_program": "CARTITUDE-6",
      "partner": "Legend Biotech",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05346835",
          "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
          "overall_status": "AVAILABLE",
          "phase": null,
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Scientific Affairs, LLC",
          "collaborators": [],
          "interventions": [
            "Cilta-cel OOS Therapy"
          ],
          "last_update": "2025-08-27",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
        }
      ],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "Localized Prostate Cancer",
      "phase": null,
      "trial_or_program": "ATLAS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04662580",
          "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Metastatic Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "ARX517",
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04662580"
        },
        {
          "nct_id": "NCT04325828",
          "title": "An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Salivary Gland Neoplasms"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "GnRH Agonist"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04325828"
        },
        {
          "nct_id": "NCT06019676",
          "title": "Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [],
          "last_update": "2025-09-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06019676"
        },
        {
          "nct_id": "NCT02721979",
          "title": "A Phase 2 Study of Apalutamide in Active Surveillance Patients",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Adenocarcinoma"
          ],
          "lead_sponsor": "University of Washington",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Questionnaire Administration"
          ],
          "last_update": "2023-02-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721979"
        },
        {
          "nct_id": "NCT04108208",
          "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Placebo",
            "Androgen-deprivation Therapy (ADT)"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108208"
        },
        {
          "nct_id": "NCT03365297",
          "title": "Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "CCTU- Cancer Theme",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2019-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03365297"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "ERLEADA (apalutamide)",
      "indication": "High Risk Prostate Cancer",
      "phase": null,
      "trial_or_program": "PROTEUS",
      "partner": "Regents of California and Memorial Sload Kettering",
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT04662580",
          "title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Metastatic Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "ARX517",
            "Apalutamide",
            "Abiraterone acetate",
            "Prednisone"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04662580"
        },
        {
          "nct_id": "NCT04325828",
          "title": "An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Salivary Gland Neoplasms"
          ],
          "lead_sponsor": "Janssen Pharmaceutical K.K.",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "GnRH Agonist"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04325828"
        },
        {
          "nct_id": "NCT06019676",
          "title": "Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients, a Multicentre Prospective Observational Study",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
          ],
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborators": [
            "Janssen, LP"
          ],
          "interventions": [],
          "last_update": "2025-09-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06019676"
        },
        {
          "nct_id": "NCT02721979",
          "title": "A Phase 2 Study of Apalutamide in Active Surveillance Patients",
          "overall_status": "TERMINATED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Adenocarcinoma"
          ],
          "lead_sponsor": "University of Washington",
          "collaborators": [
            "Janssen Scientific Affairs, LLC",
            "National Cancer Institute (NCI)"
          ],
          "interventions": [
            "Apalutamide",
            "Laboratory Biomarker Analysis",
            "Quality-of-Life Assessment",
            "Questionnaire Administration"
          ],
          "last_update": "2023-02-09",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT02721979"
        },
        {
          "nct_id": "NCT04108208",
          "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)",
          "overall_status": "ACTIVE_NOT_RECRUITING",
          "phase": null,
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Apalutamide",
            "Placebo",
            "Androgen-deprivation Therapy (ADT)"
          ],
          "last_update": "2025-12-18",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04108208"
        },
        {
          "nct_id": "NCT03365297",
          "title": "Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)",
          "overall_status": "COMPLETED",
          "phase": "Phase 2",
          "conditions": [
            "Prostate Cancer"
          ],
          "lead_sponsor": "CCTU- Cancer Theme",
          "collaborators": [
            "Janssen-Cilag Ltd."
          ],
          "interventions": [
            "Apalutamide"
          ],
          "last_update": "2019-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT03365297"
        }
      ],
      "_ctgov_best_phase": "Phase 2",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "Non Muscle Invasive Bladder Cancer BCG-naïve High Risk",
      "phase": null,
      "trial_or_program": "SunRISe-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "INLEXZO (gemcitabine intravesical system)",
      "indication": "High Risk Non Muscle Invasive Bladder Cancer BGC Experienced",
      "phase": null,
      "trial_or_program": "SunRISe-5",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Head and Neck Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "pasritamig",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT07225946",
          "title": "A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Prostatic Neoplasms, Castration-Resistant"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Docetaxel",
            "Prednisone"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07225946"
        },
        {
          "nct_id": "NCT06095089",
          "title": "A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Advanced Prostate Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-87189401"
          ],
          "last_update": "2025-12-05",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06095089"
        },
        {
          "nct_id": "NCT07164443",
          "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Metastatic Castration-resistant Prostate Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "Placebo",
            "Best Supportive Care (BSC)"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07164443"
        },
        {
          "nct_id": "NCT07082920",
          "title": "A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "JNJ-78278343",
            "JNJ-95298177"
          ],
          "last_update": "2025-12-17",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07082920"
        },
        {
          "nct_id": "NCT07319871",
          "title": "A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Prostatic Neoplasms"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Pasritamig",
            "JNJ-86974680"
          ],
          "last_update": "2026-01-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07319871"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer",
      "phase": null,
      "trial_or_program": "ORIGAMI-2",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "RYBREVANT (amivantamab)",
      "indication": "Colorectal Cancer 2L",
      "phase": null,
      "trial_or_program": "ORIGAMI-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05379595",
          "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Advanced or Metastatic Colorectal Cancer"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab IV",
            "Fluorouracil",
            "Leucovorin",
            "Oxaliplatin",
            "Irinotecan",
            "Amivantamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
        },
        {
          "nct_id": "NCT07276399",
          "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Squamous Cell Carcinoma of Head and Neck"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Pembrolizumab",
            "Carboplatin",
            "5-Flurouracil",
            "Cisplatin"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
        },
        {
          "nct_id": "NCT07227025",
          "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Carcinoma, Non-Small-Cell Lung"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Amivantamab",
            "Olomorasib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MonumenTAL-6",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TALVEY (talquetamab)",
      "indication": "Relapsed Refractory Multiple Myeloma A-CD38 Naïve",
      "phase": null,
      "trial_or_program": "MonumenTAL-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TAR-210 (RIS/erdafitinib)",
      "indication": "Intravesical Delivery System for Localized Bladder Cancer",
      "phase": null,
      "trial_or_program": "MoonRISe-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Multiple Myeloma 1-3PLs",
      "phase": null,
      "trial_or_program": "MajesTEC-3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TE NDMM maintenance",
      "phase": null,
      "trial_or_program": "MajesTEC-4",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "TIE NDMM in combination with DR",
      "phase": null,
      "trial_or_program": "MajesTEC-7",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "TECVAYLI (teclistamab)",
      "indication": "Relapsed Refractory Multiple Myeloma CD38 exposed",
      "phase": null,
      "trial_or_program": "MajesTEC-9",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT06251076",
          "title": "Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Relapsed Cancer",
            "Refractory Cancer"
          ],
          "lead_sponsor": "University Health Network, Toronto",
          "collaborators": [
            "Janssen Inc."
          ],
          "interventions": [
            "Teclistamab",
            "Tocilizumab"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06251076"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        },
        {
          "nct_id": "NCT06477783",
          "title": "Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Multiple Myeloma",
            "Hematologic Diseases"
          ],
          "lead_sponsor": "Universitaire Ziekenhuizen KU Leuven",
          "collaborators": [
            "Janssen Pharmaceutica"
          ],
          "interventions": [
            "Teclistamab"
          ],
          "last_update": "2025-03-12",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06477783"
        },
        {
          "nct_id": "NCT07110844",
          "title": "A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Amyloid Light-chain Amyloidosis"
          ],
          "lead_sponsor": "Suzanne Lentzsch, MD",
          "collaborators": [
            "Janssen Pharmaceuticals"
          ],
          "interventions": [
            "Teclistamab",
            "Daratumumab and Hyaluronidase-fihj"
          ],
          "last_update": "2025-11-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07110844"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "Bleximenib",
      "indication": "Relapsed Refractory Acute Myeloid Leukemia",
      "phase": null,
      "trial_or_program": "ALE1001",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT06852222",
          "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Placebo"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06852222"
        },
        {
          "nct_id": "NCT07295951",
          "title": "An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Acute Lymphoblastic Leukemia",
            "Acute Leukemias",
            "Acute Myeloid Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "14C-bleximenib",
            "bleximenib"
          ],
          "last_update": "2025-12-22",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07295951"
        },
        {
          "nct_id": "NCT05453903",
          "title": "A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations",
          "overall_status": "RECRUITING",
          "phase": "Phase 1",
          "conditions": [
            "Leukemia, Myeloid, Acute"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib",
            "Venetoclax (VEN)",
            "Azacitidine (AZA)",
            "Cytarabine",
            "Daunorubicin or Idarubicin"
          ],
          "last_update": "2025-12-24",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05453903"
        },
        {
          "nct_id": "NCT04811560",
          "title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Acute Leukemias",
            "Acute Myeloid Leukemia",
            "Acute Lymphoblastic Leukemia"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Bleximenib"
          ],
          "last_update": "2025-12-10",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT04811560"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "JNJ-0683 (ARX788)",
      "indication": "Breast Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-1900 (NBTXR3)",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": "Nanobiotix",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TALVEY + TECVAYLI",
      "indication": "Relapsed Refractory Multiple Myeloma",
      "phase": null,
      "trial_or_program": "RedirecTT-1",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [
        {
          "nct_id": "NCT05972135",
          "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
          "overall_status": "RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "SCRI Development Innovations, LLC",
          "collaborators": [
            "Johnson & Johnson"
          ],
          "interventions": [
            "Teclistamab",
            "Talquetamab",
            "Tocilizumab"
          ],
          "last_update": "2025-10-29",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
        },
        {
          "nct_id": "NCT06285318",
          "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
          "overall_status": "RECRUITING",
          "phase": null,
          "conditions": [
            "Relapsed/Refractory Multiple Myeloma (RRMM)"
          ],
          "lead_sponsor": "Janssen-Cilag Ltd.",
          "collaborators": [],
          "interventions": [
            "Teclistamab",
            "Talquetamab"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
        },
        {
          "nct_id": "NCT07029776",
          "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
          "overall_status": "NOT_YET_RECRUITING",
          "phase": "Phase 2",
          "conditions": [
            "Multiple Myeloma (MM)"
          ],
          "lead_sponsor": "University of Arkansas",
          "collaborators": [
            "Janssen Research & Development, LLC"
          ],
          "interventions": [
            "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
            "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
          ],
          "last_update": "2025-11-06",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
        },
        {
          "nct_id": "NCT06208150",
          "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
          "overall_status": "RECRUITING",
          "phase": "Phase 3",
          "conditions": [
            "Multiple Myeloma"
          ],
          "lead_sponsor": "Janssen Research & Development, LLC",
          "collaborators": [],
          "interventions": [
            "Talquetamab",
            "Pomalidomide",
            "Teclistamab",
            "Elotuzumab",
            "Dexamethasone",
            "Bortezomib"
          ],
          "last_update": "2025-12-19",
          "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
        }
      ],
      "_ctgov_best_phase": "Phase 3",
      "_ctgov_phase_flag": "ok"
    },
    {
      "asset": "JNJ-0387",
      "indication": "Solid Tumors",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-0631 (ARX305)",
      "indication": "Renal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-1493",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-2638",
      "indication": "Gastrointestinal Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-2761",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-3413",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4496",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4680",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4681",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4916",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-5322",
      "indication": "Multiple Myeloma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-6420",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-7446",
      "indication": "Lung Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-8177 (ARX517)",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-8377",
      "indication": "Lymphoma",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-8543",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-9401",
      "indication": "Prostate Cancer",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-9530",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-9892",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-9968",
      "indication": "Hematological Malignancies",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriasis",
      "phase": null,
      "trial_or_program": "ICONIC",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "SIMPONI (golimumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "PURSUIT 2",
      "partner": "Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Crohn's Disease",
      "phase": null,
      "trial_or_program": "UNITI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "STELARA (ustekinumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "UNIFI JR",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Juvenile Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Psoriasis",
      "phase": null,
      "trial_or_program": "PROTOSTAR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Psoriatic Arthritis Structural Damage",
      "phase": null,
      "trial_or_program": "APEX",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Ulcerative Colitis Subcutaneous Induction",
      "phase": null,
      "trial_or_program": "ASTRO",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "icotrokinra",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Warm Autoimmune Hemolytic Anemia",
      "phase": null,
      "trial_or_program": "ENERGY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Sjogren's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Hemolytic Disease of the Fetus and Newborn",
      "phase": null,
      "trial_or_program": "AZALEA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Fetal and Neonatal Alloimmune Thrombocytopenia",
      "phase": null,
      "trial_or_program": "FREESIA",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "TREMFYA (guselkumab)",
      "indication": "Pediatric Ulcerative Colitis",
      "phase": null,
      "trial_or_program": "QUASAR JR",
      "partner": "MorphoSys AG",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "icotrokinra",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Ulcerative Colitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Psoriatic Arthritis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-4804 Co-antibody Therapy",
      "indication": "Crohn's Disease",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-5939",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Systemic Lupus Erythematosus",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Idiopathic Inflammatory Myopathy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-5108",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-6848",
      "indication": "Immunological Diseases",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-7528",
      "indication": "Atopic Dermatitis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Adjunctive Treatment for Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis",
      "phase": null,
      "trial_or_program": "Vivacity MG3",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "IMAAVY (nipocalimab)",
      "indication": "Generalized Myasthenia Gravis Pediatrics",
      "phase": null,
      "trial_or_program": "VIBRANCE MG",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Treatment Resistant Depression monotherapy",
      "phase": null,
      "trial_or_program": "TRD4005",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Bipolar Mania",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "CAPLYTA (lumateperone)",
      "indication": "Pediatric Psychiatric Indications",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "nipocalimab",
      "indication": "Chronic Inflammatory Demyelinating Polyneuropathy",
      "phase": null,
      "trial_or_program": "ARISE",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "RPGR Gene Therapy",
      "indication": "Retinitis Pigmentosa",
      "phase": null,
      "trial_or_program": "LUMEOS",
      "partner": "UCL Business Plc",
      "notes": "AAV-RPGR",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "seltorexant",
      "indication": "Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms",
      "phase": null,
      "trial_or_program": "OARS",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "ITI-1284",
      "indication": "Generalized Anxiety Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Psychosis",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "ITI-1284",
      "indication": "Alzheimer's Disease-Related Agitation",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-1887 sCD59",
      "indication": "Geographic Atrophy",
      "phase": null,
      "trial_or_program": null,
      "partner": "Hemera Biosciences",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-2056 (tau active immunotherapy)",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "RETAIN",
      "partner": "AC Immune SA",
      "notes": "AC Immune ACI-35.030",
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "JNJ-5120",
      "indication": "Major Depressive Disorder",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "posdinemab",
      "indication": "Alzheimer's Disease",
      "phase": null,
      "trial_or_program": "AUTONOMY",
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "SPRAVATO (esketamine)",
      "indication": "Major Depressive Disorder with Suicidal Ideation Pediatrics",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "CABENUVA",
      "indication": "HIV Adolescents",
      "phase": null,
      "trial_or_program": null,
      "partner": "ViiV Healthcare",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "UPTRAVI (selexipag)",
      "indication": "Pediatric Pulmonary Arterial Hypertension",
      "phase": null,
      "trial_or_program": "SALTO",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "macitentan",
      "indication": "Pulmonary Arterial Hypertension 75mg",
      "phase": null,
      "trial_or_program": "UNISUS",
      "partner": "Nippon Shinyaku",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Secondary Stroke Prevention",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Acute Coronary Syndrome",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "milvexian (Factor Xla)",
      "indication": "Atrial Fibrillation",
      "phase": null,
      "trial_or_program": null,
      "partner": "Bristol Myers Squibb",
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "SIRTURO",
      "indication": "Leprosy",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    },
    {
      "asset": "SIRTURO",
      "indication": "Tuberculosis Long Acting",
      "phase": null,
      "trial_or_program": null,
      "partner": null,
      "notes": null,
      "_ctgov_matches": [],
      "_ctgov_best_phase": null,
      "_ctgov_phase_flag": "none"
    }
  ],
  "_meta": {
    "run_date_utc": "2026-01-08",
    "source_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf",
    "input_text_sha256": "c8346bd17a91794d9b776b0953bb625a6580b4ee8d53710ed2d456500a7a481d",
    "ocr_max_pages": 12,
    "ocr_dpi": 220,
    "source_type": "jnj_q4cdn_auto",
    "stored_pdf_path": "sources/jnj/2026-01-08.pdf",
    "source_sha256": "7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04",
    "doc_unchanged": true,
    "doc_unchanged_note": "Source PDF SHA256 unchanged; reused prior snapshot to avoid extraction variability.",
    "extraction_ok": true,
    "ctgov": {
      "enabled": true,
      "queried_assets": [
        "AKEEGA (niraparib/abiraterone)",
        "DARZALEX (daratumumab)",
        "IMBRUVICA (ibrutinib)",
        "INLEXZO (gemcitabine intravesical system)",
        "RYBREVANT (amivantamab)",
        "Bleximenib",
        "CARVYKTI (Ciltacabtagene autoleucel)",
        "ERLEADA (apalutamide)",
        "JNJ-1900 (NBTXR3)",
        "pasritamig",
        "TALVEY + TECVAYLI",
        "TALVEY (talquetamab)",
        "TAR-210 (RIS/erdafitinib)",
        "TECVAYLI (teclistamab)",
        "JNJ-0683 (ARX788)",
        "JNJ-0387",
        "JNJ-0631 (ARX305)",
        "JNJ-1493",
        "JNJ-2638",
        "JNJ-2761",
        "JNJ-3413",
        "JNJ-4496",
        "JNJ-4680"
      ],
      "queries_executed": 23,
      "programs_total": 101,
      "programs_with_matches": 25,
      "phase_mismatches": 0,
      "sources_path": "sources/jnj/ctgov/2026-01-08",
      "api_base": "https://clinicaltrials.gov/api/v2"
    },
    "sec_edgar": {
      "enabled": true,
      "since_date": "2026-01-08",
      "filings_considered": 0,
      "filings_with_events": 0,
      "sources_path": "sources/jnj/sec/2026-01-08"
    }
  }
}